Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Clinical Background BPC-157 was introduced in 1993 and initially studied as a potential treatment for inflammatory bowel disease due to its anti-ulcer effects
We fully expect you to use the BPC-157 you buy from Adapt Peptides within those legal boundaries
10.1039/B915804A
BPC-157 supplements are not approved treatments for gastrointestinal disorders, underscoring the importance of ongoing research in the field of gut health
131 The system, termed LNC-Ted HAKPV, offered three principal therapeutic benefits: (1) promotion of endogenous GLP-2 production to enhance intestinal growth and repair, (2) targeted anti-inflammatory action mediated through HA-KPV's modulation of the CD44/TLR4 pathways, and (3) redox-responsive release of the anti-inflammatory tripeptide KPV via disulfide bonds, activated under inflamed intestinal conditions
Common preservative systems for peptide formulations include phenoxyethanol, potassium sorbate, or commercially available broad-spectrum preservative blends
US$ 23.38
US$ 28.63
US$ 23.35
US$ 26.09
US$ 29.78
US$ 27.63
US$ 24.61
US$ 27.94